Condition: Primary Membranous Nephropathy · Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
This description comes directly from the study's public registry record.
Minghui Zhao · 0086-13501243815 · mhzhao@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, He'nan, China | Recruiting |
| Hebei General Hospital | Shijiazhuang, Hebei, China | Recruiting |
| The First Affiliated Hospital,College of Medicine,Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| Peking university first hospital | Beijing, China | Recruiting |
| Longhua Hospital Shanghai University of Traditional Chinese Medicine | Shanghai, China | Recruiting |
| Longhua Hospital Shanghai University of Traditional Chinese Medicine | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05668403